Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01538680
Registration number
NCT01538680
Ethics application status
Date submitted
21/02/2012
Date registered
24/02/2012
Date last updated
29/05/2019
Titles & IDs
Public title
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Query!
Scientific title
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Query!
Secondary ID [1]
0
0
2011-005836-25
Query!
Secondary ID [2]
0
0
15967
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
CONSIGN
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Colorectal Neoplasms
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Bowel - Back passage (rectum) or large bowel (colon)
Query!
Intervention/exposure
Study type
Expanded Access
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Regorafenib (BAY73-4506)
Treatment: Drugs: Regorafenib (BAY73-4506)
Subjects will receive 160 mg regorafenib po every day (qd) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Subjects will continue on treatment until at least one of the following occurs (main criteria):
Progressive Disease (PD). The subject may continue treatment at the investigator's discretion.
Death Unacceptable toxicity Subject withdraws consent Treating physician determines discontinuation of treatment is in the subject's best interest Substantial non-compliance with the protocol
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Eligibility
Key inclusion criteria
* Male or female subjects 18 years of age
* Life expectancy of at least 3 months
* Histological or cytological documentation of adenocarcinoma of the colon or rectum. All other histological types are excluded.
* Subjects with metastatic colorectal cancer (Stage IV)
* Progression during or within 3 months following the last administration of approved standard therapies which must include fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab and cetuximab/panitumumab (if KRAS WT) (WT: wild type)
* ECOG Performance Status of = 1 (ECOG: Eastern Cooperative Oncology Group)
* Adequate bone marrow, liver and renal function
* Women of childbearing potential and men must agree to use adequate contraception
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Prior treatment with regorafenib
* Congestive heart failure >/= New York Heart Association (NYHA) class 2
* Uncontrolled hypertension (Systolic blood pressure > 140 mmHg or diastolic pressure > 90 mmHg despite optimal medical management)
* Any hemorrhage or bleeding event >/= CTCAE Grade 3 within 4 weeks prior to the start of study medication.
* Persistent proteinuria of CTCAE Grade 3 (>3.5g/24 hours)
* Unresolved toxicity higher than CTCAE (v. 4.0) Grade 1 attributed to any prior therapy/procedure excluding alopecia, hypothyroidism and oxaliplatin induced neurotoxicity </= Grade 2
* Systemic anticancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy, and hormonal therapy during this trial or within 4 weeks (or within 6 weeks for mitomycin C) before starting to receive study medication
Query!
Study design
Purpose of the study
Query!
Allocation to intervention
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
NO_LONGER_AVAILABLE
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Query!
Recruitment hospital [1]
0
0
- Concord
Query!
Recruitment hospital [2]
0
0
- St Leonards
Query!
Recruitment hospital [3]
0
0
- Woodville South
Query!
Recruitment hospital [4]
0
0
- Footscray
Query!
Recruitment hospital [5]
0
0
- Parkville
Query!
Recruitment postcode(s) [1]
0
0
2139 - Concord
Query!
Recruitment postcode(s) [2]
0
0
2065 - St Leonards
Query!
Recruitment postcode(s) [3]
0
0
5011 - Woodville South
Query!
Recruitment postcode(s) [4]
0
0
3011 - Footscray
Query!
Recruitment postcode(s) [5]
0
0
3050 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
District of Columbia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Iowa
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Kentucky
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Louisiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Maine
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Massachusetts
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Michigan
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Minnesota
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Mississippi
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Missouri
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Nebraska
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Nevada
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
New Hampshire
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
New York
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
North Carolina
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
North Dakota
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Ohio
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Oregon
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Pennsylvania
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Rhode Island
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
South Carolina
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Tennessee
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Texas
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Virginia
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Washington
Query!
Country [32]
0
0
Austria
Query!
State/province [32]
0
0
Oberösterreich
Query!
Country [33]
0
0
Austria
Query!
State/province [33]
0
0
Steiermark
Query!
Country [34]
0
0
Austria
Query!
State/province [34]
0
0
Tirol
Query!
Country [35]
0
0
Austria
Query!
State/province [35]
0
0
Wien
Query!
Country [36]
0
0
Belgium
Query!
State/province [36]
0
0
Bruxelles - Brussel
Query!
Country [37]
0
0
Belgium
Query!
State/province [37]
0
0
Edegem
Query!
Country [38]
0
0
Belgium
Query!
State/province [38]
0
0
Leuven
Query!
Country [39]
0
0
Belgium
Query!
State/province [39]
0
0
Roeselare
Query!
Country [40]
0
0
Canada
Query!
State/province [40]
0
0
Alberta
Query!
Country [41]
0
0
Canada
Query!
State/province [41]
0
0
Ontario
Query!
Country [42]
0
0
Canada
Query!
State/province [42]
0
0
Quebec
Query!
Country [43]
0
0
Czechia
Query!
State/province [43]
0
0
Brno
Query!
Country [44]
0
0
Czechia
Query!
State/province [44]
0
0
Praha
Query!
Country [45]
0
0
Denmark
Query!
State/province [45]
0
0
Aarhus C
Query!
Country [46]
0
0
Denmark
Query!
State/province [46]
0
0
Copenhagen
Query!
Country [47]
0
0
Finland
Query!
State/province [47]
0
0
Helsinki
Query!
Country [48]
0
0
Finland
Query!
State/province [48]
0
0
HUS
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Avignon
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Bordeaux
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
CLERMONT-FERRAND Cedex 1
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Le Mans Cedex 2
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Lille Cedex
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Marseille
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Montpellier Cedex
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Nice
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Paris Cedex 15
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Paris
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Reims Cedex
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Saint Herblain
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Strasbourg Cedex
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Toulouse
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Baden-Württemberg
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Bayern
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Niedersachsen
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
Nordrhein-Westfalen
Query!
Country [67]
0
0
Germany
Query!
State/province [67]
0
0
Rheinland-Pfalz
Query!
Country [68]
0
0
Germany
Query!
State/province [68]
0
0
Sachsen-Anhalt
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
Sachsen
Query!
Country [70]
0
0
Germany
Query!
State/province [70]
0
0
Berlin
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
Hamburg
Query!
Country [72]
0
0
Greece
Query!
State/province [72]
0
0
Heraklion
Query!
Country [73]
0
0
Greece
Query!
State/province [73]
0
0
Kifissia / Athens
Query!
Country [74]
0
0
Hungary
Query!
State/province [74]
0
0
Budapest
Query!
Country [75]
0
0
Ireland
Query!
State/province [75]
0
0
Cork
Query!
Country [76]
0
0
Ireland
Query!
State/province [76]
0
0
Dublin
Query!
Country [77]
0
0
Israel
Query!
State/province [77]
0
0
Beer Sheva
Query!
Country [78]
0
0
Israel
Query!
State/province [78]
0
0
Haifa
Query!
Country [79]
0
0
Israel
Query!
State/province [79]
0
0
Jerusalem
Query!
Country [80]
0
0
Israel
Query!
State/province [80]
0
0
Petah Tikva
Query!
Country [81]
0
0
Israel
Query!
State/province [81]
0
0
Tel Aviv
Query!
Country [82]
0
0
Italy
Query!
State/province [82]
0
0
Campania
Query!
Country [83]
0
0
Italy
Query!
State/province [83]
0
0
Emilia-Romagna
Query!
Country [84]
0
0
Italy
Query!
State/province [84]
0
0
Lazio
Query!
Country [85]
0
0
Italy
Query!
State/province [85]
0
0
Liguria
Query!
Country [86]
0
0
Italy
Query!
State/province [86]
0
0
Lombardia
Query!
Country [87]
0
0
Italy
Query!
State/province [87]
0
0
Marche
Query!
Country [88]
0
0
Italy
Query!
State/province [88]
0
0
Puglia
Query!
Country [89]
0
0
Italy
Query!
State/province [89]
0
0
Sicilia
Query!
Country [90]
0
0
Italy
Query!
State/province [90]
0
0
Toscana
Query!
Country [91]
0
0
Italy
Query!
State/province [91]
0
0
Veneto
Query!
Country [92]
0
0
Mexico
Query!
State/province [92]
0
0
Distrito Federal
Query!
Country [93]
0
0
Mexico
Query!
State/province [93]
0
0
Guanajuato
Query!
Country [94]
0
0
Mexico
Query!
State/province [94]
0
0
Jalisco
Query!
Country [95]
0
0
Mexico
Query!
State/province [95]
0
0
Aguascalientes
Query!
Country [96]
0
0
Mexico
Query!
State/province [96]
0
0
Oaxaca
Query!
Country [97]
0
0
Mexico
Query!
State/province [97]
0
0
Toluca
Query!
Country [98]
0
0
Mexico
Query!
State/province [98]
0
0
Veracruz
Query!
Country [99]
0
0
Netherlands
Query!
State/province [99]
0
0
Amsterdam
Query!
Country [100]
0
0
Netherlands
Query!
State/province [100]
0
0
Leiden
Query!
Country [101]
0
0
Norway
Query!
State/province [101]
0
0
Oslo
Query!
Country [102]
0
0
Poland
Query!
State/province [102]
0
0
Bialystok
Query!
Country [103]
0
0
Poland
Query!
State/province [103]
0
0
Poznan
Query!
Country [104]
0
0
Portugal
Query!
State/province [104]
0
0
Coimbra
Query!
Country [105]
0
0
Portugal
Query!
State/province [105]
0
0
Porto
Query!
Country [106]
0
0
Russian Federation
Query!
State/province [106]
0
0
Kazan
Query!
Country [107]
0
0
Russian Federation
Query!
State/province [107]
0
0
Krasnodar
Query!
Country [108]
0
0
Russian Federation
Query!
State/province [108]
0
0
Moscow
Query!
Country [109]
0
0
Russian Federation
Query!
State/province [109]
0
0
Obninsk
Query!
Country [110]
0
0
Russian Federation
Query!
State/province [110]
0
0
Orenburg
Query!
Country [111]
0
0
Russian Federation
Query!
State/province [111]
0
0
St. Petersburg
Query!
Country [112]
0
0
Spain
Query!
State/province [112]
0
0
Andalucía
Query!
Country [113]
0
0
Spain
Query!
State/province [113]
0
0
Barcelona
Query!
Country [114]
0
0
Spain
Query!
State/province [114]
0
0
Cantabria
Query!
Country [115]
0
0
Spain
Query!
State/province [115]
0
0
A Coruña
Query!
Country [116]
0
0
Spain
Query!
State/province [116]
0
0
Madrid
Query!
Country [117]
0
0
Spain
Query!
State/province [117]
0
0
Málaga
Query!
Country [118]
0
0
Spain
Query!
State/province [118]
0
0
Sevilla
Query!
Country [119]
0
0
Spain
Query!
State/province [119]
0
0
Valencia
Query!
Country [120]
0
0
Sweden
Query!
State/province [120]
0
0
Linköping
Query!
Country [121]
0
0
Sweden
Query!
State/province [121]
0
0
Uppsala
Query!
Country [122]
0
0
Switzerland
Query!
State/province [122]
0
0
Basel-Stadt
Query!
Country [123]
0
0
Switzerland
Query!
State/province [123]
0
0
Graubünden
Query!
Country [124]
0
0
Switzerland
Query!
State/province [124]
0
0
Bern
Query!
Country [125]
0
0
Switzerland
Query!
State/province [125]
0
0
Genève
Query!
Country [126]
0
0
Switzerland
Query!
State/province [126]
0
0
Zürich
Query!
Country [127]
0
0
United Kingdom
Query!
State/province [127]
0
0
Leicestershire
Query!
Country [128]
0
0
United Kingdom
Query!
State/province [128]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Bayer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a phase III B, prospective, interventional, open-label, single-arm, multicenter study to provide regorafenib to subjects diagnosed with metastatic colorectal cancer who have failed after standard therapy and for whom no therapy alternatives exist, in the time between positive results and approval / availability on the market, and to collect safety data for regorafenib until market access. Regorafenib is an oral (i.e. taken by mouth) multi-targeted kinase inhibitor. A kinase inhibitor targets certain key proteins that are essential for the survival of the cancer cell. By specifically targeting these proteins, regorafenib may stop cancer growth. The growth of the tumor may be decreased by preventing these specific proteins from functioning. The primary endpoint of this study will be safety.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01538680
Query!
Trial related presentations / publications
Van Cutsem E, Martinelli E, Cascinu S, Sobrero A, Banzi M, Seitz JF, Barone C, Ychou M, Peeters M, Brenner B, Hofheinz RD, Maiello E, Andre T, Spallanzani A, Garcia-Carbonero R, Arriaga YE, Verma U, Grothey A, Kappeler C, Miriyala A, Kalmus J, Falcone A, Zaniboni A. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. Oncologist. 2019 Feb;24(2):185-192. doi: 10.1634/theoncologist.2018-0072. Epub 2018 Sep 6.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bayer Study Director
Query!
Address
0
0
Bayer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT01538680
Download to PDF